



---

# OPTO CIRCUITS (INDIA) LIMITED. (UNIT II) 100% EOU

---

**Date: 16<sup>th</sup> June 2017**

**THE STOCK EXCHANGE, BOMBAY  
PHIROZE JEEJEBHOY TOWERS  
DALAL STREET  
MUMBAI-400 001.**

**NATIONAL STOCK EXCHANGE OF INDIA LTD,  
EXCHANGE PLAZA,  
BANDRA – KURLA COMPLEX,  
BANDRA (E)  
MUMBAI – 400 051.**

Dear Sir

Subject: Investors Update letter.

We are enclosing herewith the Investors's update letter issued by the company regarding progress and significant events.

This is for your information.

Thanking you,

Yours faithfully,  
for OPTO CIRCUITS (INDIA) LTD.,

  
**Authorised Signatory**



# OPTO CIRCUITS (INDIA) LIMITED. (UNIT II) 100% EOU

## Opto Circuits (I) Ltd. Investor Update June 2017

Bangaluru – June 16 2017. Effective this quarter, the management of Opto Circuits aims to keep updating our shareholders of progress and significant events. This is with the aim to enhance the communication of our goals, vision and accomplishments to our valued shareholders.

Over the past 2 years your company has gone through significant challenges that have resulted in a decline in revenue and legal battles. The hostile takeover of our Cardiac Science subsidiary in the U.S. in October of 2015 is the main cause and was an event that will be in the courts in both India and the United States for some time to come.

We are optimistic that we will prevail with our legal claims in excess of USD 160 Million against various parties that were involved in the hostile takeover and subsequent restructuring and sale of our then subsidiary, Cardiac Science.

We are also dealing with the right-sizing of our balance sheet via continued negotiations with our lenders for restructuring of debt. Further, apart from bringing on Board a Financial management professional down the lane, unviable operational segments are being closed and operational level re-organisation is taking place. In conjunction with this effort, we are pursuing various strategic alternatives that we anticipate will provide additional capital and business opportunities for your company.

In parallel to the efforts outlined above, your management is also working on various initiatives to accelerate the revenue and profit margins of our group of companies.

To that length we continue to invest in new technology development, mainly in our vascular interventional business unit, EuroCor GmbH in Germany. EuroCor is one of the global leaders in Drug-coated balloon and stent devices (DCB and DES) and possesses very unique and patented technology that we believe provides us with significant clinical and commercial advantages. Recent clinical trials have clearly shown superior performance of the EuroCor FREEWAY™ Drug-coated balloon system vs. competing devices.

The market size for these products has grown from USD 100 Million 3 years ago to over USD 800 Million today and is expected to double again over the next 3 to 5 years. Lastly we are continuing to enhance our Criticare and Unetixs Vascular products and service offerings, again with the aim to build sales and profits.

Our profit from operations has been growing and we expect that trend to continue over the next few quarters, driven by both cost savings and increase in sales and profitability.

Sincerely,

  
Vinod Ramnani  
Chairman.

